David Demanse

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Johanna C. Bendell, Jordi Rodón, Howard A. Burris et al. · Journal of Clinical Oncology · 2011 · 686 citations · Full text

Medicine, Oncology, Pharmacology +14

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study

Dejan Juric, Jordi Rodón, Josep Tabernero et al. · Journal of Clinical Oncology · 2018 · 439 citations

Medicine, Oncology, Pharmacology +14

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Philippe L. Bédard, Josep Tabernero, Filip Jankú et al. · Clinical Cancer Research · 2014 · 326 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

Dejan Juric, Filip Jankú, Jordi Rodón et al. · JAMA Oncology · 2018 · 260 citations · Full text

Medicine, Oncology, Pharmacology +15

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

H. Burris, Jordi Rodón, Shaleekha Sharma et al. · Journal of Clinical Oncology · 2010 · 109 citations

Medicine, Oncology, Pharmacology +10